A biotech startup backed by OpenAI is set to begin human clinical trials of an antibody drug next year, according to The Wall Street Journal. The company uses artificial intelligence to speed up drug development, and its candidate therapy will be tested against a specific disease. The update points to a new step for OpenAI’s involvement in AI-assisted drug discovery.
The reported trial marks a move beyond early-stage research and toward clinical translation. While the report did not name the company or disclose the disease target, it said the candidate drug is being advanced with the help of AI tools designed to shorten parts of the research and development process. The development highlights how artificial intelligence is being applied in biotechnology as companies push drug candidates from lab work into human testing.
An OpenAI-backed biotech startup plans to begin human clinical trials of an antibody drug next year, according to The Wall Street Journal.
The company uses artificial intelligence to accelerate drug development, and its candidate therapy will be tested for a specific disease.
The reported step is the latest development tied to OpenAI in AI-assisted drug discovery, showing how artificial intelligence is moving from basic research into clinical translation.
This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan. Disclaimer:
The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.
Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.
